As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus
Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon
Executive Summary
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.
You may also be interested in...
Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: CAR-Ts move into earlier treatment; Sanofi bets big on super antibodies; takeaways from the world’s largest dermatology conference; China moves towards imported COVID vaccines; and R&D experts discuss the superbug threat.
Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.